INLEXZO

What is this medication? Inrebic is a prescription medication primarily used to treat adults with certain types of myelofibrosis, which is a rare type of bone marrow cancer. It is specifically indicated for patients who have intermediate-2 or high-risk primary or secondary myelofibrosis, including post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis. The medication works as a kinase inhibitor, targeting specific proteins like Janus Associated Kinase 2 to help reduce the size of an enlarged spleen and improve symptoms such as fatigue, night sweats, and bone pain. This medication is typically administered orally in the form of capsules and is often prescribed for patients who have not responded well to other treatments or as a primary therapy for those with high-risk disease profiles. Because it can cause serious side effects, such as potential brain toxicity or gastrointestinal issues, it is closely monitored by healthcare professionals throughout the course of treatment. Patients are usually required to undergo regular blood tests to check their thiamine levels and liver function while taking this drug to ensure its continued safety and effectiveness.